In 2012 Novartis did a strategic evaluation of their middleware strategy which consisted of two traditional, full-featured, on-premises solutions supporting over 140 active integrations. Both were proving slow and expensive to develop and maintain, and the team was spending time and resources on upgrades and maintenance rather than business value.